Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 13/20 | 1.00 |
| ▸ | HPGDS | O60760 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | TP53 | P04637 | 2/20 | 0.55 |
| ▸ | HPGD | P15428 | 2/20 | 0.55 |
| ▸ | HTT | P42858 | 2/20 | 0.55 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.52 |
| ▸ | BAZ1A | Q9NRL2 | 1/20 | 0.52 |
| ▸ | MTOR | P42345 | 1/20 | 0.52 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.52 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3937867 | 0.89 | EPHX2 (1.00) | EPHX2HPGDTRPV4 | |
| SCHEMBL3946002 | 0.88 | EPHX2 (1.00) | EPHX2HPGDSALDH1A1TP53HPGD | |
| SCHEMBL3347907 | 0.84 | EPHX2 (1.00) | EPHX2HPGDSALDH1A1TP53HPGD | |
| SCHEMBL13503897 | 0.81 | LMNA (0.68) | EPHX2ALDH1A1HPGDTRPV4 | |
| SCHEMBL3936950 | 0.81 | EPHX2 (0.72) | EPHX2HPGDSALDH1A1TP53HPGD | |
| SCHEMBL3946025 | 0.81 | EPHX2 (0.71) | EPHX2HPGDSALDH1A1TP53HPGD | |
| SCHEMBL4001213 | 0.79 | EPHX2 (1.00) | EPHX2TRPV4 | |
| SCHEMBL13503647 | 0.79 | EPHX2 (0.81) | EPHX2HPGD | |
| SCHEMBL10202129 | 0.78 | EPHX2 (0.81) | EPHX2HPGDSALDH1A1TP53HPGD | |
| SCHEMBL27308576 | 0.76 | EPHX2 (0.65) | EPHX2ALDH1A1TP53HPGDHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101495119-A | Soluble epoxide hydrolase inhibitors | ARETE THERAPEUTICS INC (US) | 2009-07-29 | — | — | CN | claimed |
| EP-2046329-A2 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | Arete Therapeutics, INC. (US) | 2009-04-15 | — | — | EP | claimed |
| US-20080032978-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. | 2008-02-07 | — | — | US | claimed |
| WO-2008016884-A2 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. (US) | 2008-02-07 | — | — | WO | claimed |
| CN-101495119-A | Soluble epoxide hydrolase inhibitors | ARETE THERAPEUTICS INC (US) | 2009-07-29 | — | — | CN | disclosed |
| EP-2046329-A2 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | Arete Therapeutics, INC. (US) | 2009-04-15 | — | — | EP | disclosed |
| US-20080032978-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. | 2008-02-07 | — | — | US | disclosed |
| WO-2008016884-A2 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. (US) | 2008-02-07 | — | — | WO | disclosed |
| US-20080032978-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. | 2008-02-07 | — | — | US | disclosed |
| US-20080032978-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. | 2008-02-07 | — | — | US | disclosed |
| WO-2008016884-A2 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. (US) | 2008-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080032978-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | EPHX1, EPHX2, NCEH1 | EPHX2 2/4885HPGDS 42/4885ALDH1A1 586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.